Trinity Biotech to implement 30-for-1 ADS ratio change

Trinity Biotech plc announced on July 22, 2026 that it plans to change the ratio of its American depositary shares representing Class A ordinary shares, moving from one ADS per twenty Class A ordinary shares to one ADS per six hundred Class A ordinary shares. Trinity Biotech plc, listed on Nasdaq under TRIB, said it plans to change the ratio of its American depositary shares representing its Class A ordinary shares from one ADS representing twenty Class A ordinary shares to one ADS representing six hundred Class A ordinary shares.¹

For current ADS holders, the change works out to a reverse split of 1-for-30. The company said the adjustment carries the same practical effect as a 30-to-1 reverse ADS split and is meant to help the company regain compliance with Nasdaq's $1.00 minimum bid price rule, and to open the stock to a wider range of investors who may have avoided it while it traded under $5.00.¹ The underlying Class A ordinary shares themselves are not being changed.¹

The ratio change is expected to take effect on the Nasdaq Global Market at the opening of trading on July 24, 2026 Eastern time.¹ Current ADS holders will be required to exchange every thirty old ADSs for one new ADS through depositary bank The Bank of New York Mellon.¹ The ADSs will keep trading on Nasdaq under the ticker "TRIB."¹

No fractional new ADSs will be issued; instead, the depositary will aggregate and sell fractional entitlements and distribute the net proceeds, after fees, taxes, and expenses, to affected holders.¹ Trinity Biotech said the ADS price is expected to rise proportionally but gave no assurance that the post-change price will match or exceed thirty times the prior price.¹

Trinity Biotech describes itself as a commercial-stage biotechnology company working in human diagnostics and diabetes management, including wearable biosensors, and says it recently entered the wearable biosensor field by acquiring biosensor assets from Waveform Technologies Inc.¹ The company also said its Trinovium subsidiary is applying its fluid manufacturing and analytical know-how to build liquid cooling systems for AI data center infrastructure.¹